TradeFlare's AI research teams analysed ELVN on 9 market nights between May 4, 2026 and September 11, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 11, 2026 | BUY | $56.23 | $64.66 / $47.80 | -9.0% | -24.6% | The stock is in an uptrend and the fundamental and sentiment teams are bullish, suggesting potential for further upside. |
| September 1, 2026 | BUY | $57.89 | $72.36 / $49.21 | -0.7% | -20.8% | The setup is based on a technical pullback within a longer-term bullish trend, supported by strong fundamentals and sentiment, suggesting a multi-week recovery potential. |
| August 31, 2026 | BUY | $57.86 | $67.50 / $49.18 | +2.6% | -19.7% | The positive fundamental and sentiment outlook, coupled with a technical pullback, suggests a medium-term upward trend. |
| May 12, 2026 | BUY | $39.59 | $44.19 / $33.65 | -5.0% | -12.5% | The stock is consolidating near support, and a clear catalyst is needed for a buy decision in this neutral market. |
| May 11, 2026 | BUY | $40.75 | — / — | +0.1% | -8.8% | The current technicals are neutral to bearish, conflicting with the bullish fundamentals and sentiment, requiring a clearer technical signal. |
| May 8, 2026 | BUY | $40.29 | — / — | +1.4% | -17.5% | Positive clinical trial data for CML drug candidate. |
| May 7, 2026 | SELL | $41.20 | — / — | +6.9% | -13.8% | Positive clinical trial data for CML drug candidate. |
| May 6, 2026 | HOLD | $41.58 | — / — | +5.7% | -13.9% | Positive clinical trial data for oncology drug candidates. |
| May 4, 2026 | HOLD | $41.70 | — / — | -4.8% | -14.6% | Positive Phase 1b clinical data for ELVN-001. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.